Literature DB >> 17241256

Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine.

Claudius Malerczyk1, Deborah J Briggs, David W Dreesen, Angelika Banzhoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17241256     DOI： 10.1111/j.1708-8305.2006.00097.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  6 in total

1.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

4.  Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels.

Authors:  David Brown; Anthony R Fooks; Martin Schweiger
Journal:  Adv Prev Med       Date:  2011-05-25

5.  Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.

Authors:  Y Bui; M Sow; E Cambron-Goulet; E Levac; F Milord
Journal:  Can Commun Dis Rep       Date:  2015-03-05

6.  Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial.

Authors:  Mark A Matson; Eran Schenker; Michal Stein; Vladislava Zamfirova; Huy-Binh Nguyen; Garrett E Bergman
Journal:  Hum Vaccin Immunother       Date:  2019-09-24       Impact factor: 3.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.